Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H16N2O2.ClH |
Molecular Weight | 280.75 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.O=C1NC=CC2=CC(OC3CCNCC3)=CC=C12
InChI
InChIKey=KMNVOGVCCZNVNU-UHFFFAOYSA-N
InChI=1S/C14H16N2O2.ClH/c17-14-13-2-1-12(9-10(13)3-8-16-14)18-11-4-6-15-7-5-11;/h1-3,8-9,11,15H,4-7H2,(H,16,17);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C14H16N2O2 |
Molecular Weight | 244.289 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
SAR407899 is a potent, ATP-competitive Rho kinase inhibitor. It antihypertensive action in animals. Sanofi is developing SAR 407899 for the treatment of microvascular angina (Syndrome X). It was previously being developed in clinical trials for the treatment of diabetic neuropathies, diabetic nephropathies, erectile dysfunction, pulmonary hypertension, hypertension and kidney disorders, but development was discontinued for those indications.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19597037 |
36.0 nM [Ki] | ||
Target ID: CHEMBL3231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19597037 |
276.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator​
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [IC50 21.3174 uM] | ||||
no | ||||
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19597037
Curator's Comment: SAR407899 is in clinical trials but dosage and regimen are unknown. http://adisinsight.springer.com/drugs/800026023
rats: (0.01 to 0.30 mg/kg IV), (orally at 1, 3, 10, and 30 mg/kg)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19597037
SAR407899 effectively inhibited THP-1 migration with an IC50 of 2.5 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 19:43:44 UTC 2023
by
admin
on
Thu Jul 06 19:43:44 UTC 2023
|
Record UNII |
AD9C9XVB9T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
923262-96-8
Created by
admin on Thu Jul 06 19:43:45 UTC 2023 , Edited by admin on Thu Jul 06 19:43:45 UTC 2023
|
PRIMARY | |||
|
42635918
Created by
admin on Thu Jul 06 19:43:45 UTC 2023 , Edited by admin on Thu Jul 06 19:43:45 UTC 2023
|
PRIMARY | |||
|
AD9C9XVB9T
Created by
admin on Thu Jul 06 19:43:45 UTC 2023 , Edited by admin on Thu Jul 06 19:43:45 UTC 2023
|
PRIMARY | |||
|
DTXSID80655294
Created by
admin on Thu Jul 06 19:43:45 UTC 2023 , Edited by admin on Thu Jul 06 19:43:45 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
SOLVATE->ANHYDROUS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|